ENA0000GenomicsConnectivity Map, Cancer Program, The Broad Institutehttps://www.ebi.ac.uk/ena/browser/view/PRJNA289156Homo sapiensThe Library of Integrated Cellular Signatures (LINCS) is an NIH program which funds the generation of perturbational profiles across multiple cell and perturbation types, as well as read-outs, at a massive scale. The LINCS Center for Transcriptomics at the Broad Institute uses the L1000 high-throughput gene-expression assay to build a Connectivity Map which seeks to enable the discovery of functional connections between drugs, genes and diseases through analysis of patterns induced by common gene-expression changes. This SubSeries is part of SuperSeries GSE70138: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70138 Overall design: LINCS aims to enable a functional understanding of biology by cataloging changes in gene expression and other cellular processes that occur when cells are exposed to a variety of perturbing agents. The Broad Institute LINCS Center for Transcriptomics contributes to this collaborative effort by application of the Connectivity Map concept. In brief, the study design involves the generation of a compendium of transcriptional expression data from cultured human cells treated with small-molecule and genetic loss/gain of function perturbagens. These measurements are made using the L1000 high-throughput gene-expression assay that enables data generation at an unprecedented scale. The data are processed through a computational system, that converts raw fluorescence intensities into differential gene expression signatures. The data at each stage of the pre-processing are available: Level 1 (LXB) - raw, unprocessed flow cytometry data from Luminex scanners. One LXB file is generated for each well of a 384-well plate, and each file contains a fluorescence intensity value for every observed analyte in the well. Level 2 (GEX) - gene expression values per 1,000 genes after deconvolution from Luminex beads. Level 3 (Q2NORM) - gene expression profiles of both directly measured landmark transcripts plus inferred genes. Normalized using invariant set scaling followed by quantile normalization. Level 4 (Z-SCORES) - signatures with differentially expressed genes computed by robust z-scores for each profile relative to control (PC relative to plate population as control; VC relative to vehicle control)ENAadenomas, MUTYH-associated polyposis, MUTYH-related AFAP, RUTBC3, MUTYH-related attenuated familial adenomatous polyposis, rabGAPLP, type 2, L-methionine aminopeptidase activity, MUTYH-Associated Polyposis, wide/broad, methionine aminopeptidase activity, familial adenomatous polyposis 2, MYH-associated polyposis, autosomal recessive familial adenomatous polyposis, Maps, RabGAP-5, MYH-Associated Polyposis, broad., RABGAP5, autosomal recessive multiple colorectal adenomas, wide, RUSC3, MUTYH-related attenuated FAP, multiple colorectal, 2, MAP syndrome, MUTYH-related attenuated familial polyposis coli, familial adenomatous polyposis, MAP, peptidase M activity, FAP2, autosomal recessive, colorectal adenomatous polyposisadenomas, MUTYH-associated polyposis, MUTYH-related AFAP, RUTBC3, MUTYH-related attenuated familial adenomatous polyposis, rabGAPLP, type 2, L-methionine aminopeptidase activity, MUTYH-Associated Polyposis, wide/broad, methionine aminopeptidase activity, familial adenomatous polyposis 2, MYH-associated polyposis, autosomal recessive familial adenomatous polyposis, Maps, RabGAP-5, MYH-Associated Polyposis, broad., RABGAP5, autosomal recessive multiple colorectal adenomas, wide, RUSC3, MUTYH-related attenuated FAP, multiple colorectal, 2, MAP syndrome, MUTYH-related attenuated familial polyposis coli, familial adenomatous polyposis, MAP, peptidase M activity, FAP2, autosomal recessive, colorectal adenomatous polyposis0.00.00.00.00.00falseL1000 Connectivity Map perturbational profiles from Broad Institute LINCS Center for Transcriptomics (NIH U54HL127366) [part 5]L1000 Connectivity Map perturbational profiles from Broad Institute LINCS Center for Transcriptomics (NIH U54HL127366) [part 5]2016-11-042015-07-16PRJNA289156GSE705689606